What patents tell us about drug repurposing for cancer: A landscape analysis
Publication date: Available online 20 September 2019Source: Seminars in Cancer BiologyAuthor(s): Hermann A.M. MuckeABSTRACTIntellectual property documents (patents and their published applications) are not only collections of legal exclusivity claims but also repositories of scientific and technical information, even though they are not peer reviewed. We have identified and analyzed international disclosures concerning drug repurposing for cancer that were published under the Patent Convention Treaty during the past five years, and show this burgeoning field from an angle that is not routinely captured in review papers of the field. We find that patenting activity for cancer-related new uses for known compounds has been quite constant recently and has targeted mainly small molecule active ingredients that are currently marketed as drugs. Universities contributed most applications, closely followed by corporations. The strong representation of non-academic research institutes from the public and private sector and foundations was surprising and indicates that drug repurposing for cancer has transcended the classical corporate-academia dichotomy. Many of the identified patent documents report findings that are not reflected in the peer review literature (e.g., sumatriptan for mycosis fungoides) or appear there only later (e.g., ibudilast for glioblastoma). Synergistic combinations of several repurposed compounds were also identified, as were two documents related to the repurpo...
Abstract Mogamulizumab, approved by the FDA for relapsed or refractory mycosis fungoides and Sézary syndrome, improves progression-free survival compared to vorinostat in the largest trial to date in cutaneous T-cell lymphoma, with particular efficacy in leukemic disease, but carries a risk of immune-mediated toxicities with concomitant depletion of regulatory T-cells. PMID: 31615932 [PubMed - as supplied by publisher]
ConclusionTSEBT improved disease symptoms and significantly improved emotional domains of patients ’ quality of life in patients with MF or SS. In addition, our results indicate that maintenance or adjuvant therapy after TSEBT may improve the PFS.
The molecular weight of methotrexate (MTX) makes cutaneous penetration difficult. Oxygen flow could enhance the skin permeation of MTX diluted in the LP3 carrier system. This pilot study aims to assess the efficacy, safety and tolerance of oxygen-flow-administered (OFA)-LP3-MTX3% for treating superficial skin cancers. Patients with superficial basal cell carcinoma (sBCC)(n=12), extramammary Paget ’s disease (EMPD)(n=5), mycosis fungoides classic type (CMF) (n=10) and folliculotropic (FMF) (n=6) were included in the study and were treated with 4 weekly applications of OFA-LP3-MTX3%.
The prevalence of mycosis fungoides / S ézary syndrome (MF/SS) is higher in the African American (AA)/black population compared to Caucasians in the United States and worse outcomes have been observed in AA/black patients.
Clinical and laboratory diagnostics of mycosis fungoides (MF), the most common cutaneous lymphoma is challenging. Our previous work described 4 promising markers of S ézary syndrome (SS): T-plastin, Twist, NKp46 and KIR3DL2 (Michel et al. 2013). Tox has been shown to be an additional marker for MF and SS. The aim of the present study was to confirm this combination of blood-derived markers in a validation cohort of SS, erythodermic and earlier MF for improving d iagnosis and predicting prognosis. Patients with a confirmed diagnosis of MF or SS and patients with other skin diseases were included.
We examined the relationship between nitrogen mustard (NM)-induced lymphomatoid papulosis (LyP) in patients with mycosis fungoides (MF). Nine patients were included who were initially diagnosed with MF and subsequently developed LyP in the setting of NM induced inflammation. The average time from initiation of NM therapy to development of LyP was 5.2 months. The majority of patients presented to their follow-up visit with new red bumps, most commonly located on the buttocks/lower extremities, with symptoms of pain and pruritus in 6/9 patients.
Cutaneous T-cell lymphomas, CTCLs, comprise a group of malignancies largely represented by two subtypes, mycosis fungoides (MF) and S ézary syndrome (SS). The incidence of CTCL has increased appreciably since the 1970’s, but the pathogenesis is poorly understood. Recent studies have demonstrated clustering of CTCL patient in several geographic areas suggesting that environmental factors may play a role in CTCL pathogenesis. A r etrospective chart review was conducted using the STAT data set from the Florida Cancer Data System registry.
Introduction: Thiazides (TZ) have been reported to be associated with an increased risk for both malignant melanoma (MM) and keratinocyte cancers (BCC and SCC). Moreover, although an association between TZ and the most common subtypes: mycosis fungoides (MF) and S ézary syndrome (SS) has previously been reported, there have been no large population studies reporting data for such an association with CTCL overall. The aim of this study is to explore the association between all CTCL and chronic TZ exposure in a large “real world-setting” database: the Nort hwestern Medicine Enterprise Data Warehouse (NMEDW...
An 82-year-old man with a history of prostate cancer presented with several months of enlarging ulcerated tumors and nodules on the upper and lower extremities. The patient had numerous tumors>7 cm in diameter, including a large grouping of 5-6 on his left anterior thigh, a cobblestone plaque on the right posterior calf, and innumerable discrete nodules on the bilateral forearms. Punch biopsy was performed and revealed a dense dermal nonepidermotropic infiltrate of neoplastic CD3+ CD4+ CD30- T cells with convoluted cerebriform nuclei.
Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, has a dismal prognosis in advanced stages. The success of immune checkpoint inhibitors (ICI) in treating advanced malignancies has not extended to MF. There is an urgent need to identify predictive biomarkers, and to advance immunotherapies in MF. Neoantigens are ‘new’ peptides, generated by somatic mutations in tumour cells, that evoke an immune response. As tumour-specific markers, neoantigens are an attractive immunotherapeutic target.